These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1321908)

  • 21. Thiopyranol[2,3,4-c,d]indoles as inhibitors of 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 synthase.
    Hutchinson JH; Charleson S; Evans JF; Falgueyret JP; Hoogsteen K; Jones TR; Kargman S; Macdonald D; McFarlane CS; Nicholson DW
    J Med Chem; 1995 Oct; 38(22):4538-47. PubMed ID: 7473582
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC; Ritchie DM; Ferro MP; Kirchner T; Wachter MP; Anderson DW; Rosenthale ME; Capetola RJ
    J Pharmacol Exp Ther; 1994 Dec; 271(3):1399-408. PubMed ID: 7996452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of 5-lipoxygenase inhibitors in biochemical and functional in vivo assays.
    Smith WG; Shaffer AF; Currie JL; Thompson JM; Kim S; Rao T; Isakson PC
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1332-8. PubMed ID: 8531100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
    Tateson JE; Randall RW; Reynolds CH; Jackson WP; Bhattacherjee P; Salmon JA; Garland LG
    Br J Pharmacol; 1988 Jun; 94(2):528-39. PubMed ID: 2840160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A rat air pouch model for evaluating the efficacy and selectivity of 5-lipoxygenase inhibitors.
    Zweifel BS; Hardy MM; Anderson GD; Dufield DR; Pufahl RA; Masferrer JL
    Eur J Pharmacol; 2008 Apr; 584(1):166-74. PubMed ID: 18295198
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-lipoxygenase inhibitory activity of zileuton.
    Carter GW; Young PR; Albert DH; Bouska J; Dyer R; Bell RL; Summers JB; Brooks DW
    J Pharmacol Exp Ther; 1991 Mar; 256(3):929-37. PubMed ID: 1848634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Indazolinones, a new series of redox-active 5-lipoxygenase inhibitors with built-in selectivity and oral activity.
    Bruneau P; Delvare C; Edwards MP; McMillan RM
    J Med Chem; 1991 Mar; 34(3):1028-36. PubMed ID: 1848292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A-78773: a selective, potent 5-lipoxygenase inhibitor.
    Bell RL; Brooks DW; Young PR; Lanni C; Stewart AO; Bouska J; Malo PE; Carter GW
    J Lipid Mediat; 1993; 6(1-3):259-64. PubMed ID: 8395248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics.
    Müller-Peddinghaus R; Fruchtmann R; Ahr HJ; Beckermann B; Bühner K; Fugmann B; Junge B; Matzke M; Kohlsdorfer C; Raddatz S
    J Lipid Mediat; 1993; 6(1-3):245-8. PubMed ID: 8395246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
    Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
    Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy model.
    Raychaudhuri A; Chertock H; Chovan J; Jones LS; Kimble EF; Kowalski TJ; Peppard J; White DH; Satoh Y; Roland D
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Apr; 355(4):470-4. PubMed ID: 9109363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of the anti-inflammatory activity of selective 5-lipoxygenase inhibitors with dexamethasone and colchicine in a model of zymosan induced inflammation in the rat knee joint and peritoneal cavity.
    Griffiths RJ; Li SW; Wood BE; Blackham A
    Agents Actions; 1991 Mar; 32(3-4):312-20. PubMed ID: 1650524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ca2+ ionophore A23187-stimulated secretion of azurophil granules in human polymorphonuclear leukocytes is largely mediated by endogenously formed leukotriene B4.
    Hatzelmann A; Fruchtmann R; Mohrs KH; Raddatz S; Müller-Peddinghaus R
    Biochem Pharmacol; 1994 Jul; 48(1):31-9. PubMed ID: 8043028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.
    Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Murakami M; Oketani K; Inoue T
    J Med Chem; 1994 Sep; 37(19):3062-70. PubMed ID: 7932529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the new 5-lipoxygenase inhibitor E6080 on leukotriene release in vitro.
    Sakuma Y; Katayama S; Tsunoda H; Abe S; Yamatsu I; Katayama K
    Int Arch Allergy Immunol; 1992; 97(4):267-73. PubMed ID: 1375926
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro effects of E3040, a dual inhibitor of 5-lipoxygenase and thromboxane A(2) synthetase, on eicosanoid production.
    Oketani K; Nagakura N; Harada K; Inoue T
    Eur J Pharmacol; 2001 Jun; 422(1-3):209-16. PubMed ID: 11430933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
    Ku EC; Raychaudhuri A; Ghai G; Kimble EF; Lee WH; Colombo C; Dotson R; Oglesby TD; Wasley JW
    Biochim Biophys Acta; 1988 Apr; 959(3):332-42. PubMed ID: 2833314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
    Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A
    Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
    Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel imidazole compounds as a new series of potent, orally active inhibitors of 5-lipoxygenase.
    Mano T; Stevens RW; Ando K; Nakao K; Okumura Y; Sakakibara M; Okumura T; Tamura T; Miyamoto K
    Bioorg Med Chem; 2003 Sep; 11(18):3879-87. PubMed ID: 12927848
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.